Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

Rhea-AI Summary

Acadia Pharmaceuticals (NASDAQ: ACAD) will announce its fourth quarter and full year 2022 financial results on February 27, 2023, after U.S. market close.

The company will host a conference call and webcast that same day at 4:30 p.m. Eastern Time to discuss these results and operational updates. Interested participants can register for the call via Acadia's website.

Acadia is focused on neuroscience breakthroughs, developing therapies for conditions like Parkinson's disease psychosis, schizophrenia, and Alzheimer's disease psychosis.

Company to host conference call and webcast on Monday, February 27, 2023, at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2022 financial results on Monday, February 27, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 27, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations.

The conference call may be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call. The registration link will also be available on Acadia’s website, www.acadia.com under the investors section and will be archived there until April 3, 2023.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Rett syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements regarding the timing of future events. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization. For a discussion of these and other factors, please refer to Acadia’s annual report on Form 10-K for the year ended December 31, 2021 as well as Acadia’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Acadia undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230214005788/en/

Media Contact:

Acadia Pharmaceuticals Inc.

Deb Kazenelson

(818) 395-3043

media@acadia-pharm.com

Investor Contact:

Acadia Pharmaceuticals Inc.

Mark Johnson, CFA

(858) 261-2771

ir@acadia-pharm.com

Source: Acadia Pharmaceuticals Inc.

FAQ

When will Acadia Pharmaceuticals report its 2022 financial results?

Acadia Pharmaceuticals will report its fourth quarter and full year 2022 financial results on February 27, 2023.

What time is the Acadia Pharmaceuticals conference call on February 27, 2023?

The conference call will take place at 4:30 p.m. Eastern Time on February 27, 2023.

How can I access the conference call for Acadia Pharmaceuticals?

Participants can register for the conference call through Acadia's website to receive the dial-in information.

What is Acadia Pharmaceuticals known for?

Acadia Pharmaceuticals is known for developing therapies for neurological disorders, including the first approved therapy for Parkinson’s disease psychosis.